The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.

ABSTRACT:

Objective

Ivabradine, a specific heart rate lowering therapy, has been shown in a randomised placebo-controlled study, Systolic HF Treatment with the If Inhibitor Ivabradine Trial (SHIfT), to significantly reduce the composite end point of cardiovascular death and hospitalisation for worsening heart failure (HF) in patients with systolic HF who are in sinus rhythm and with a heart rate ≥70 bpm, when added to optimised medical therapy (HR: 0.82, 95% CI 0.75 to 0.90, p<0.0001). We assessed the cost effectiveness of ivabradine, from a UK National Health Service perspective, based on the results of SHIfT.

Methods

A Markov model estimated the cost effectiveness of ivabradine compared with standard care for two cohorts of patients with HF (heart rate ≥75 bpm in line with the EU la

SUBMITTER: Griffiths A 

PROVIDER: S-EPMC4078716 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature